Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)CancerinhibitorJuvenile idiopathic arthritisPediatricsrateResearchrheumatologyriskTNFTreatment

Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

Michele B. Kaufman, PharmD, BCGP  |  March 20, 2017

Recent research analyzed factors influencing the selection of the first-line biologic medications and the real-life factors that lead to switching from those medications to other biologics in treating rheumatoid arthritis (RA). The study compared the use of abatacept and tocilizumab with a tumor necrosis factor alpha inhibitor (TNFi).1,2 Participants were enrolled in the Lombardy Rheumatology…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:biologic therapiesdrugMedicationpatient carephysicianRheumatic DiseaseRheumatoid arthritisrheumatologistrheumatology

On the Road in Rajasthan: Vehicular-Caused Bone, Joint Damage in India

David S. Pisetsky, MD, PhD  |  March 20, 2017

In the good old days, physicians routinely made house calls. The decision to visit the literal bedside of a patient was practical: hospital services were primitive and often offered too little benefit to justify an emergency journey by the patient. These physicians carried leather bags, sometimes called Gladstones, that were filled with instruments for eventualities…

Filed under:From the College Tagged with:bonedamageimpoverishedIndiainjuryjointPainRajasthanrheumatologytrauma

The ACR Teams with National Bone Health Alliance to Increase Focus on Osteoporosis, Bone Disease

Kurt Ullman  |  February 15, 2017

Bone health in general, and osteoporosis in particular, is among the most common conditions seen in rheumatology practices. The ACR recently joined the National Bone Health Alliance (NBHA) to reach out to other stakeholders. “In 2004, the Surgeon General of the United States published a report on osteoporosis that discussed in depth the gaps in…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Awarenessbone breakbone diseaseEducationFracturesNational Bone Health AllianceOsteoporosis

Denosumab Does Not Increase Risk of Infection in RA Patients

Lara C. Pullen, PhD  |  February 13, 2017

New research dispels the fear that denosumab will increase the risk of infection in vulnerable populations with rheumatoid arthritis when it is prescribed in combination with TNF inhibitors or other biologics. Investigators found the treatment did not increase infection risk beyond what is expected for the patients’ disease, comorbidities and medications…

Filed under:ConditionsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:2016 ACR/ARHP Annual MeetingACR/ARHP Annual MeetingdenosumabInfectionOsteoporosisRheumatoid Arthritis (RA)

Insights into Drug-Related Interactions in Older Adults

Michele B. Kaufman, PharmD, BCGP  |  February 9, 2017

A study showed that prior hospitalization and the use of multiple medications are risk factors for drug and drug–disease interactions…

Filed under:Drug Updates Tagged with:drug interactionelderlyNonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDs

Monkey Business Images/shutterstock.com

Medical Paradoxes in Clinic, Lab Should Encourage Physicians to Reappraise Ideas about Health and Disease

Simon M. Helfgott, MD  |  January 19, 2017

Wash your hands. This most basic tenet of proper hygiene has been drummed into our heads for years. It’s an obvious infection prevention activity, yet for years, compliance among physicians and other caregivers has been lackluster. To rectify this matter, regulatory agencies began auditing hospital staff adherence to this axiom of infection prevention. Not only…

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:clinicDietDiseaseDrugslaboutcomeparadoxpatient careResearchrheumatologistrheumatologySmoking

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Filed under:AnalgesicsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:CancerFDAFood and Drug AdministrationFX006HIVkneeKnee Osteoarthritis (OA)Painpioglitazone

Research Underscores Need to Assess Oral Health in Patients with Systemic Sclerosis

Research Underscores Need to Assess Oral Health in Patients with Systemic Sclerosis

Kurt Ullman  |  November 16, 2016

Oral health is not frequently considered within the sphere of a rheumatologist’s practice. However, recent results published by the Canadian Scleroderma Research Group (CSRG) point out the importance of assessing oral health in patients with systemic sclerosis (SSc). Result of 3-Year Grant Between 2008 and 2011, 163 patients with SSc and 231 controls were entered…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:DiagnosisHealthcareManagementoral healthpatient careResearchRheumatic DiseaserheumatologySystemic sclerosistherapyTreatment

ACR Opposes DXA Reimbursement Cuts

Kelly Tyrrell  |  October 31, 2016

The Centers for Medicare and Medicaid Services (CMS) plans to significantly reduce reimbursement for dual-energy X-ray absorptiometry (DXA),—used to measure bone density, diagnose osteoporosis and help prevent fractures—performed as a hospital outpatient service in the 2017 Hospital Outpatient Prospective Payment System (HOPPS). If finalized, by 2023 it will cut payment for the DXA testing by 37%….

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:bipartisan bill H.R.2461dual-energy x-ray absorptiometryDXAreimbursement cuts

  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 43
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences